October 12, 2012 — An advisory committee to the Centers for Disease Control and Prevention has released recommendations on the use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth ...

Give the 13-valent pneumococcal conjugate vaccine to senior patients Give the 13-valent pneumococcal conjugate vaccine along with the 23-valent pneumococcal polysaccharide vaccine to all patients aged ...

Compared with a 23-valent pneumococcal polysaccharide vaccine, a 13-valent pneumococcal conjugate vaccine was more cost-effective among adults in the United States. “Conjugate vaccines have been shown ...

September 7, 2010 — Guidelines have been updated for use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults, according to a report in the September 3 issue of MMWR. Morbidity and ...

Please provide your email address to receive an email when new articles are posted on . Although vaccines have reduced the burden of pneumococcal disease, pneumonia due to Streptococcus pneumoniae and ...

Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...

Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...